Objective
HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous prime–boost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the “risk curve” in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.
Fields of science
- natural sciencesbiological sciencesgenetics
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
SW7 2AZ LONDON
United Kingdom
See on map
Participants (26)
OX1 2JD Oxford
See on map
75654 Paris
See on map
08916 Barcelona
See on map
00161 Roma
See on map
3400 Klosterneuburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
Participation ended
08036 Barcelona
See on map
1081 HV Amsterdam
See on map
75015 PARIS 15
See on map
20132 Milano
See on map
38058 Grenoble
See on map
WC2R 2LS London
See on map
17177 Stockholm
See on map
91054 Erlangen
See on map
N6A 3K7 Ontario -London
See on map
1024 Budapest
See on map
Participation ended
1090 Wien
See on map
Participation ended
55131 Mainz
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28029 Madrid
See on map
Participation ended
1013 NH Amsterdam
See on map
3010 Melbourne
See on map
2052 Sydney
See on map
Participation ended
CB10 1SA SAFFRON WALDEN
See on map
10004 New York
See on map
SO17 1BJ Southampton
See on map
08035 Barcelona
See on map